Skip to content

Impact of Forced Diuresis on the Residual Fragment Rate After Flexible Ureteroscopy for Destruction of Kidney Stones With Laser

FIRESTONES : Impact of Forced Diuresis on the Residual Fragment Rate After Flexible Ureteroscopy for Destruction of Kidney Stones With Laser: a Randomized Controlled Two-parallel Group Multicenter Trial With Blinding Evaluation

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05916963
Acronym
FIREStones
Enrollment
374
Registered
2023-06-23
Start date
2024-01-04
Completion date
2026-04-03
Last updated
2025-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Kidney Stone

Brief summary

In view of the positive results of the numerous studies conducted on forced diuresis after extra-corporeal lithotripsy, the investigators chose to evaluate forced diuresis by injection of Furosemide associated with intravenous hydration, which has never before been the subject of a specific analysis.

Detailed description

Flexible ureteroscopy is the most common technique to treat kidney stones and is the treatment of choice in France. Kidney stones destruction requires its laser pulverization into small fragments in order to remove them through the ureter or improve their spontaneous expulsion along the urinary tract. However, most of the time, all the micro-fragments and dust created during stone destruction cannot be extracted using our surgical tools, and may stay intra-renally at the end of the procedure. Although these micro-fragments are expected to disappear spontaneously by the natural flushing and peristalsis of the upper urinary tract, they remain at risk of stagnation that could be the nest of new aggregation and stone formation. Adjuvant treatments (such as forced diuresis, inversion or mechanical pressure) were previously described to improve the expulsion of stone fragments after extra-corporeal shock wave lithotripsy. Nevertheless, the impact of adjuvant treatment after flexible ureteroscopy remains unclear and mainly theoretical. In view of the positive results of the numerous studies conducted on forced diuresis after extra-corporeal lithotripsy, the investigators chose to evaluate forced diuresis by injection of Furosemide associated with intravenous hydration, which has never before been the subject of a specific analysis. Loop diuretics (including Furosemide) significantly increase diuresis, which results in a greater flow of urine into the renal cavities, improving the chances of evacuating the residual fragments of the stone destroyed during flexible ureteroscopy, before they can sediment in the fundus of the renal calices or in the pyelon. Therefore, the investigators hypothesize that a forced diuresis with an injection of Furosemide at the end of ureteroscopy could improve the micro-fragments and stones dust clearance.

Interventions

Injection of 40 mg of Furosemide during 10 minutes after the end of the flexible ureteroscopy for destruction of kidney stones with laser.

Sponsors

University Hospital, Tours
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Masking description

The study will not be blinded except for the outcome assessment: radiologists in charge of interpreting CT-Scans will be blinded.

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Patients ≥ 18 years old and \< 80 years old * With the need to perform a flexible ureteroscopy with destruction of the kidney stones with laser * Participants covered by or entitled to social security * Written informed consent obtained from the participant * Ability for participant to comply with the requirements of the study

Exclusion criteria

* Persons covered by articles L1121-5 to L1121-8 of the CSP (corresponding to all protected persons: pregnant women, parturients, nursing mothers, persons deprived of their liberty by judicial or administrative decision, minors, and persons subject to a legal protection measure: guardianship or trusteeship) * Contra-indication to Furosemide: * Hyper-sensitivity to the active substance or one of the excipients * Hyper-sensitivity to Sulfonamide * Renal failure with oligo-anuria refractory to Furosemide * Hypokalemia \< 3,5 mmol/L * Severe hyponatremia * Hypovolemia with or without hypotension or dehydration * Ongoing hepatitis, hepatic insufficiency severe and hepatic encephalopathy * Patient having Furosemide as usual treatment * Patient requiring an injection of Aminoside or Vancomycin before or during the procedure * Participation in other interventional research with an investigational drug or medical device

Design outcomes

Primary

MeasureTime frameDescription
Rate of stone free patientsAt 3 monthsRate of stone-free patients 3 months after a flexible ureteroscopy for renal stone laser destruction, evaluated on the low dose abdomino-pelvic CT-Scan. A centralized review of the images will be performed by two specialized radiologists, in a blind and crossed way to allow a homogenization of the results

Secondary

MeasureTime frameDescription
Rate of urinary infectionFrom baseline to 30 daysRate of post-operative urinary tract infection will be assessed within 30 days after surgery on the combination of: * Fever higher than 38.5°C and/or, * Chills and/or, * Clinical symptoms (supra-pubic pain, dysuria, pollakiuria, urgency, urinary burning, back pain radiating to the genitals, hematuria) and/or * Positive urine culture with a significant bacteriuria threshold defined as bacteriuria ≥10\^5 UFC/mL with one or two bacterial species.
Pain in a scaleDuring the hospital stayPost-operative pain will be assessed on numerical pain scale in the recovery room, in the service and at the discharge. Pain scale is from 0 (no pain) to 10 (as bad as it could be nothing else matters)
Opioid consumptionDuring the hospital stay, an average of 1 dayThe use of opioids will be reported
Number of participants with adverse eventsFrom baseline to 3 months, an average of 1 dayNumber of participants with Furosemide adverse events

Countries

France

Contacts

Primary ContactMarie-Lou LETOUCHE, MD
marielou.letouche@gmail.com+33247474665

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 7, 2026